Shares of Nuformix plc (LON:NFX – Get Free Report) rose 6.7% on Tuesday . The company traded as high as GBX 0.19 and last traded at GBX 0.19. 1,201,807 shares were traded during trading, a decline of 97% from the average daily volume of 35,847,605 shares. The stock had previously closed at GBX 0.18.
Nuformix Stock Performance
The company’s fifty day moving average price is GBX 0.18 and its 200-day moving average price is GBX 0.22. The stock has a market cap of £4.31 million, a P/E ratio of -5.63 and a beta of 1.54.
Nuformix (LON:NFX – Get Free Report) last released its quarterly earnings results on Thursday, May 28th. The company reported GBX (0.02) EPS for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Recommended Stories
- Five stocks we like better than Nuformix
- 2 Space and Defense Stocks Turning Backlogs Into Revenue Growth
- Energy Fuels Just Made a Bold Bet on Rare Earth Magnets
- Washington’s Quantum Push Puts IBM and IonQ on the Throne
- FedEx’s Earnings Drop May Be Missing the Bigger Freight Story
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
